Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2206 to 2220 of 8917 results

  1. Subcutaneous nivolumab–relatlimab for untreated unresectable or metastatic melanoma in people 12 years and over [TSID 12178]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Cyanoacrylate glue for hernia mesh fixation (MT707)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  3. O2Matic pro 100 (MT746)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  4. Subcutaneous pembrolizumab with platinum-based chemotherapy for untreated metastatic non-small-cell lung cancer [TSID12213]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  5. Lomitapide for treating homozygous familial hypercholesterolaemia in people 5 to 17 years [TSID 12085]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  6. Eptinezumab for preventing cluster headache attacks TSID 12087

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Selumetinib granules for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children 1 to 6 years [TSID12092]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Linaclotide acetate for treating functional constipation in people 6 to 17 years [TSID12125]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Clindamycin for treating bacterial vaginosis in females aged 12 and older [TSID 12127]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Ustekinumab for treating moderately to severely active ulcerative colitis in children aged 2 to 17 years [TSID 12128]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  12. Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  13. Lebrikizumab for treating atopic dermatitis in children [TSID12133]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  14. Vedolizumab for treating moderately to severely active ulcerative colitis in people 2 to 17 years [TSID12134]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  15. CFHealthHub for managing cystic fibrosis during the COVID-19 pandemic

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation